GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: UK launch

>what type of net would GTC receive from Leo - are you still at the high teens?<

GTC’s guidance is a combined royalty and transfer price from Leo in the mid-to-high teens as a percentage of sales. According to GTC, the above is net of GTC’s production cost and hence is pure profit. However, a possible “gotcha” in this calculation is that GTC’s cost of goods on a unit basis may initially be higher than what Leo will cover if the production volume is very low, leading to a lower net-profit margin during the early days of the product launch.

>Also, are you surprised at the daily medicinal charge for ATRYN in the UK?<

I would have guessed $15K, so the actual per-day price (assuming the cited amount is accurate) is about 50% higher.

In a country as stingy with drug reimbursement as the UK, such a high price must mean that the efficacy and safety of ATryn in the HD population is considered to be beyond reproach.